tulobuterol has been researched along with Asthma in 41 studies
Asthma: A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Compared with oral salbutamol sulfate, tulobuterol patch has a better therapeutic efficacy and a higher safety in children with mild or moderate acute asthmatic attack." | 9.17 | [Efficacy and safety of tulobuterol patch versus oral salbutamol sulfate in children with mild or moderate acute attack of bronchial asthma: a comparative study]. ( Bao, YX; Lin, Q; Liu, QH, 2013) |
| "Tulobuterol patch (Tulo) is often used for treatment of elder patient with asthma in Japan." | 9.16 | [Clinical effects of budesonide/formoterol combination drug in elder patients with asthma compared with budesonide plus tulobuterol patch combination treatment]. ( Haruta, Y; Kondoh, K; Mukaida, K; Onari, Y, 2012) |
| "Whether the additive effects of the tulobuterol patch (TP), the world's first transdermal beta2-agonist preparation, are useful in asthma patients receiving inhaled corticosteroid (ICS) is unclear." | 9.14 | Effects of the addition of Beta2-agonist tulobuterol patches to inhaled corticosteroid in patients with asthma. ( Haruta, Y; Hozawa, S; Terada, M; Yamakido, M, 2009) |
| "Patients with inadequately controlled asthma on inhaled corticosteroid (400 to 1,600 microg/day chlorofluorocarbon beclomethasone equivalent) were treated with concomitant salmeterol (n = 18) or sustained-release tulobuterol (patch) (n = 18), or the inhaled corticosteroid dose was doubled (add-on) (n = 13) to compare clinical efficacy." | 9.12 | Comparison of the clinical efficacy of salmeterol and sustained-release tulobuterol (patch) on inadequately controlled asthma patients on inhaled corticosteroids. ( Fujimoto, K; Komatsu, Y; Kubo, K; Urushihata, K; Yasuo, M, 2006) |
| "Sixty-four patients with persistent asthma receiving 200 to 800 microg of fluticasone propionate daily were enrolled in this switchover study." | 9.12 | Addition of transdermal or inhaled long-acting Beta2-agonists in adult asthmatic patients treated with inhaled corticosteroids: switchover study from tulobuterol patch to salmeterol dry powder inhaler. ( Kita, H; Kobayashi, Y; Kudou, M; Yasuba, H, 2007) |
| "To evaluate the efficacy and safety of tulobuterol tape in mild and moderate persistent asthma patients." | 9.12 | [The efficacy and safety of tulobuterol tape in mild and moderate persistent asthma patients]. ( Cao, ZL; Chen, BY; Chen, X; He, J; He, QY; Lin, JT; Su, N; Xiao, Y; Yan, XX; Yang, M, 2007) |
| "In fifteen patients with asthma tulobuterol, a new beta 2-adrenoceptor agonist, given by inhalation in 100 micrograms increments up to a cumulative dose of 600 micrograms produced dose related increases in both the FEV1 and FVC." | 9.06 | Bronchodilator activity of a new inhaled beta 2-adrenoceptor agonist, tulobuterol and its protective effect in exercise-induced asthma. ( Patel, KR, 1986) |
| "The objective of this open randomized cross-over study was to compare the clinical efficacy and safety of a recently introduced beta-2 mimetic, tulobuterol, with fenoterol in asthma patients." | 9.06 | Open cross-over comparison of tulobuterol and fenoterol in asthmatic adult patients. ( Azanza, JR; Dal-Re, R; Rivero, A; Sanchez, J, 1988) |
| "Fifteen asthmatic patients participated in a dose-ranging study using tulobuterol syrup in single doses of 10 to 60 mcg/kg." | 9.06 | Tulobuterol in childhood asthma: single dose ranging and repeated oral dose comparative studies. ( Javier, MA; Noche, ML, 1986) |
| "Aggravation of asthmatic response (asthmatic attack, 2 cases) and adverse events (tremor, 1 case) due to a switch from a brand-name tulobuterol tape to a generic tape were recently reported." | 7.78 | [Questionnaire survey on the change of asthmatic response, adverse events and product usability due to drug switching between name-brand and generic tulobuterol tapes]. ( Hori, S; Izumi, T; Miki, A; Satoh, H; Sawada, Y, 2012) |
| "We investigated the efficacy of nighttime transdermal tulobuterol (beta2-adrenoceptor agonist) chronotherapy for nocturnal asthma by assessing changes both in the frequency of symptoms and features of the circadian rhythm in peak expiratory flow (PEF), a measure of airway caliber." | 7.73 | Alteration of the circadian rhythm in peak expiratory flow of nocturnal asthma following nighttime transdermal beta2-adrenoceptor agonist tulobuterol chronotherapy. ( Burioka, N; Endo, M; Fukuoka, Y; Igawa, K; Miyata, M; Nakazaki, H; Shimizu, E; Suyama, H, 2005) |
| "We report the pharmacokinetics and pharmacodynamics of tulobuterol patch, HN-078, in the treatment of childhood asthma." | 7.69 | Pharmacokinetics and pharmacodynamics of the tulobuterol patch, HN-078, in childhood asthma. ( Akimoto, K; Ebisawa, M; Iikura, Y; Ishizu, H; Kabayama, H; Miura, K; Sakaguchi, N; Tsubaki, T; Uchiyama, H; Yagi, K, 1995) |
| " Usually, oral dosage forms of beta 2-agonists have been used, but side effects such as palpitation and tremor have been reported because of excessive serum levels around Tmax." | 6.41 | [Development of transdermal formulation of tulobuterol for the treatment of bronchial asthma]. ( Kato, H; Nagata, O; Nakano, Y; Suzuki, T; Yamazaki, M, 2002) |
| "Bronchial asthma is a chronic disease which is currently treated using various inhalants." | 5.62 | Sustained release of tulobuterol from graphene oxide laden hydrogel to manage asthma. ( Chen, Y; Jin, S; Luo, L; Luo, S; Wu, B; Xu, C; Yang, T, 2021) |
| "We suggest that this treatment of bronchial asthma may protect against endotoxin contained in inhaled house dust." | 5.35 | Tulobuterol patch maintains diaphragm muscle contractility for over twenty-four hours in a mouse model of sepsis. ( Miura, M; Murakami, Y; Nishio, T; Sasaki, K; Shindoh, C; Shishido, R, 2009) |
| "2." | 5.31 | Effects of sustained-release tulobuterol on asthma control and beta-adrenoceptor function. ( Ito, Y; Kondo, M; Kume, H; Suzuki, R; Takagi, K; Yamaki, K, 2002) |
| "Compared with oral salbutamol sulfate, tulobuterol patch has a better therapeutic efficacy and a higher safety in children with mild or moderate acute asthmatic attack." | 5.17 | [Efficacy and safety of tulobuterol patch versus oral salbutamol sulfate in children with mild or moderate acute attack of bronchial asthma: a comparative study]. ( Bao, YX; Lin, Q; Liu, QH, 2013) |
| "Tulobuterol patch (Tulo) is often used for treatment of elder patient with asthma in Japan." | 5.16 | [Clinical effects of budesonide/formoterol combination drug in elder patients with asthma compared with budesonide plus tulobuterol patch combination treatment]. ( Haruta, Y; Kondoh, K; Mukaida, K; Onari, Y, 2012) |
| "Whether the additive effects of the tulobuterol patch (TP), the world's first transdermal beta2-agonist preparation, are useful in asthma patients receiving inhaled corticosteroid (ICS) is unclear." | 5.14 | Effects of the addition of Beta2-agonist tulobuterol patches to inhaled corticosteroid in patients with asthma. ( Haruta, Y; Hozawa, S; Terada, M; Yamakido, M, 2009) |
| "Patients with inadequately controlled asthma on inhaled corticosteroid (400 to 1,600 microg/day chlorofluorocarbon beclomethasone equivalent) were treated with concomitant salmeterol (n = 18) or sustained-release tulobuterol (patch) (n = 18), or the inhaled corticosteroid dose was doubled (add-on) (n = 13) to compare clinical efficacy." | 5.12 | Comparison of the clinical efficacy of salmeterol and sustained-release tulobuterol (patch) on inadequately controlled asthma patients on inhaled corticosteroids. ( Fujimoto, K; Komatsu, Y; Kubo, K; Urushihata, K; Yasuo, M, 2006) |
| "To evaluate the efficacy and safety of tulobuterol tape in mild and moderate persistent asthma patients." | 5.12 | [The efficacy and safety of tulobuterol tape in mild and moderate persistent asthma patients]. ( Cao, ZL; Chen, BY; Chen, X; He, J; He, QY; Lin, JT; Su, N; Xiao, Y; Yan, XX; Yang, M, 2007) |
| "Sixty-four patients with persistent asthma receiving 200 to 800 microg of fluticasone propionate daily were enrolled in this switchover study." | 5.12 | Addition of transdermal or inhaled long-acting Beta2-agonists in adult asthmatic patients treated with inhaled corticosteroids: switchover study from tulobuterol patch to salmeterol dry powder inhaler. ( Kita, H; Kobayashi, Y; Kudou, M; Yasuba, H, 2007) |
| "Fifteen asthmatic patients participated in a dose-ranging study using tulobuterol syrup in single doses of 10 to 60 mcg/kg." | 5.06 | Tulobuterol in childhood asthma: single dose ranging and repeated oral dose comparative studies. ( Javier, MA; Noche, ML, 1986) |
| "The objective of this open randomized cross-over study was to compare the clinical efficacy and safety of a recently introduced beta-2 mimetic, tulobuterol, with fenoterol in asthma patients." | 5.06 | Open cross-over comparison of tulobuterol and fenoterol in asthmatic adult patients. ( Azanza, JR; Dal-Re, R; Rivero, A; Sanchez, J, 1988) |
| "In fifteen patients with asthma tulobuterol, a new beta 2-adrenoceptor agonist, given by inhalation in 100 micrograms increments up to a cumulative dose of 600 micrograms produced dose related increases in both the FEV1 and FVC." | 5.06 | Bronchodilator activity of a new inhaled beta 2-adrenoceptor agonist, tulobuterol and its protective effect in exercise-induced asthma. ( Patel, KR, 1986) |
| "Aggravation of asthmatic response (asthmatic attack, 2 cases) and adverse events (tremor, 1 case) due to a switch from a brand-name tulobuterol tape to a generic tape were recently reported." | 3.78 | [Questionnaire survey on the change of asthmatic response, adverse events and product usability due to drug switching between name-brand and generic tulobuterol tapes]. ( Hori, S; Izumi, T; Miki, A; Satoh, H; Sawada, Y, 2012) |
| "Tulobuterol patches are long-acting bronchodilators for percutaneous absorption including the β(2)-adrenoreceptor agonist tulobuterol, as a main ingredient, used for long-term management of pediatric asthma." | 3.76 | Comparative study of skin permeation profiles between brand and generic tulobuterol patches. ( Abe, T; Arisaka, O; Fukuda, H; Yoshihara, S, 2010) |
| "We investigated the efficacy of nighttime transdermal tulobuterol (beta2-adrenoceptor agonist) chronotherapy for nocturnal asthma by assessing changes both in the frequency of symptoms and features of the circadian rhythm in peak expiratory flow (PEF), a measure of airway caliber." | 3.73 | Alteration of the circadian rhythm in peak expiratory flow of nocturnal asthma following nighttime transdermal beta2-adrenoceptor agonist tulobuterol chronotherapy. ( Burioka, N; Endo, M; Fukuoka, Y; Igawa, K; Miyata, M; Nakazaki, H; Shimizu, E; Suyama, H, 2005) |
| "We report the pharmacokinetics and pharmacodynamics of tulobuterol patch, HN-078, in the treatment of childhood asthma." | 3.69 | Pharmacokinetics and pharmacodynamics of the tulobuterol patch, HN-078, in childhood asthma. ( Akimoto, K; Ebisawa, M; Iikura, Y; Ishizu, H; Kabayama, H; Miura, K; Sakaguchi, N; Tsubaki, T; Uchiyama, H; Yagi, K, 1995) |
| "Tulobuterol is a synthetic beta-adrenergic agonist which, when administered orally, is a potent, long-acting bronchodilator." | 2.67 | Can a new beta 2-agonist reduce the mortality of asthma? ( Aldons, PM, 1990) |
| "Tulobuterol is a new synthetic beta 2-agonist with potent and prolonged bronchodilator activity when given by oral and inhaled routes." | 2.67 | Prolonged treatment with oral and inhaled tulobuterol does not induce airways tachyphlaxis. ( Patel, KR, 1990) |
| " Usually, oral dosage forms of beta 2-agonists have been used, but side effects such as palpitation and tremor have been reported because of excessive serum levels around Tmax." | 2.41 | [Development of transdermal formulation of tulobuterol for the treatment of bronchial asthma]. ( Kato, H; Nagata, O; Nakano, Y; Suzuki, T; Yamazaki, M, 2002) |
| " When chronic symptoms necessitate maintenance treatment, the frequency of dosing may become a deciding factor in the selection of a bronchodilator." | 2.37 | Tulobuterol in the management of obstructive airways disease in adults. ( Patel, KR, 1985) |
| "Bronchial asthma is a chronic disease which is currently treated using various inhalants." | 1.62 | Sustained release of tulobuterol from graphene oxide laden hydrogel to manage asthma. ( Chen, Y; Jin, S; Luo, L; Luo, S; Wu, B; Xu, C; Yang, T, 2021) |
| "Persistent cough is a frequent cause of doctor and hospital visits, and its incidence may be increasing." | 1.39 | Cough variant and cough-predominant asthma are major causes of persistent cough: a multicenter study in Japan. ( Adachi, M; Akiyama, K; Hasegawa, M; Inoue, H; Kimura, G; Kobayashi, H; Niimi, A; Ohbayashi, H; Sagara, H; Takahashi, K; Wakayama, T; Yamauchi, K; Yokoe, T, 2013) |
| "We suggest that this treatment of bronchial asthma may protect against endotoxin contained in inhaled house dust." | 1.35 | Tulobuterol patch maintains diaphragm muscle contractility for over twenty-four hours in a mouse model of sepsis. ( Miura, M; Murakami, Y; Nishio, T; Sasaki, K; Shindoh, C; Shishido, R, 2009) |
| "2." | 1.31 | Effects of sustained-release tulobuterol on asthma control and beta-adrenoceptor function. ( Ito, Y; Kondo, M; Kume, H; Suzuki, R; Takagi, K; Yamaki, K, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (21.95) | 18.7374 |
| 1990's | 5 (12.20) | 18.2507 |
| 2000's | 17 (41.46) | 29.6817 |
| 2010's | 9 (21.95) | 24.3611 |
| 2020's | 1 (2.44) | 2.80 |
| Authors | Studies |
|---|---|
| Luo, S | 1 |
| Jin, S | 1 |
| Yang, T | 1 |
| Wu, B | 1 |
| Xu, C | 1 |
| Luo, L | 1 |
| Chen, Y | 1 |
| Hong, JG | 1 |
| Li, Z | 1 |
| Lin, Q | 1 |
| Liu, QH | 1 |
| Bao, YX | 1 |
| Niimi, A | 2 |
| Ohbayashi, H | 1 |
| Sagara, H | 1 |
| Yamauchi, K | 1 |
| Akiyama, K | 2 |
| Takahashi, K | 1 |
| Inoue, H | 2 |
| Wakayama, T | 1 |
| Kobayashi, H | 1 |
| Hasegawa, M | 1 |
| Kimura, G | 1 |
| Yokoe, T | 1 |
| Adachi, M | 2 |
| Matsumoto, H | 1 |
| Ito, I | 1 |
| Oguma, T | 1 |
| Otsuka, K | 1 |
| Takeda, T | 1 |
| Nakaji, H | 1 |
| Tajiri, T | 1 |
| Iwata, T | 1 |
| Nagasaki, T | 1 |
| Mishima, M | 1 |
| Shindoh, C | 1 |
| Murakami, Y | 1 |
| Shishido, R | 1 |
| Sasaki, K | 1 |
| Nishio, T | 1 |
| Miura, M | 1 |
| Hozawa, S | 1 |
| Haruta, Y | 2 |
| Terada, M | 1 |
| Yamakido, M | 1 |
| Yoshihara, S | 2 |
| Fukuda, H | 1 |
| Abe, T | 2 |
| Arisaka, O | 2 |
| Tamura, G | 3 |
| Ichinose, M | 1 |
| Fukuchi, Y | 1 |
| Miyamoto, T | 1 |
| Izumi, T | 1 |
| Hori, S | 1 |
| Satoh, H | 1 |
| Miki, A | 1 |
| Sawada, Y | 1 |
| Onari, Y | 1 |
| Mukaida, K | 1 |
| Kondoh, K | 1 |
| Katsunuma, T | 1 |
| Fujisawa, T | 1 |
| Nagao, M | 1 |
| Akasawa, A | 1 |
| Nomura, I | 1 |
| Yamaoka, A | 1 |
| Kondo, H | 1 |
| Masuda, K | 1 |
| Yamaguchi, K | 1 |
| Terada, A | 1 |
| Ikeda, M | 1 |
| Nishioka, K | 1 |
| Adachi, Y | 1 |
| Kurihara, K | 1 |
| Kume, H | 2 |
| Kondo, M | 1 |
| Ito, Y | 1 |
| Suzuki, R | 1 |
| Yamaki, K | 1 |
| Takagi, K | 1 |
| Tsurikisawa, N | 1 |
| Taniguchi, M | 1 |
| Suzuki, S | 1 |
| Horiguchi, T | 2 |
| Kondo, R | 2 |
| Miyazaki, J | 2 |
| Torigoe, H | 2 |
| Tachikawa, S | 1 |
| Fukumokto, K | 1 |
| Burioka, N | 1 |
| Miyata, M | 1 |
| Endo, M | 1 |
| Fukuoka, Y | 1 |
| Suyama, H | 1 |
| Nakazaki, H | 1 |
| Igawa, K | 1 |
| Shimizu, E | 1 |
| Yamada, Y | 1 |
| Fujimoto, K | 1 |
| Komatsu, Y | 1 |
| Yasuo, M | 1 |
| Urushihata, K | 1 |
| Kubo, K | 1 |
| Nishiyama, O | 1 |
| Taniguchi, H | 1 |
| Kondoh, Y | 1 |
| Kimura, T | 1 |
| Kato, K | 1 |
| Shimokata, K | 1 |
| Su, N | 1 |
| Lin, JT | 1 |
| Yang, M | 1 |
| Chen, X | 1 |
| He, J | 1 |
| He, QY | 1 |
| Cao, ZL | 1 |
| Chen, BY | 1 |
| Xiao, Y | 1 |
| Yan, XX | 1 |
| Kobayashi, Y | 1 |
| Yasuba, H | 1 |
| Kudou, M | 1 |
| Kita, H | 1 |
| Mita, S | 1 |
| Takahashi, T | 1 |
| Iikura, Y | 1 |
| Uchiyama, H | 1 |
| Akimoto, K | 1 |
| Ebisawa, M | 1 |
| Sakaguchi, N | 1 |
| Tsubaki, T | 1 |
| Ishizu, H | 1 |
| Kabayama, H | 1 |
| Yagi, K | 1 |
| Miura, K | 1 |
| Fujimori, K | 1 |
| Suzuki, E | 1 |
| Gejyo, F | 1 |
| Ojima, F | 1 |
| Nakamura, H | 1 |
| Ebihara, M | 1 |
| Shoji, T | 1 |
| Tomike, H | 1 |
| Nakagawa, Y | 1 |
| Numao, T | 1 |
| Fukuda, T | 1 |
| Kato, H | 1 |
| Nagata, O | 1 |
| Yamazaki, M | 1 |
| Suzuki, T | 1 |
| Nakano, Y | 1 |
| Aldons, PM | 1 |
| Rühle, KH | 1 |
| Dorow, P | 1 |
| Schmitz-Schumann, H | 1 |
| Patel, KR | 4 |
| Tomioka, S | 1 |
| Kuroiwa, H | 1 |
| Pérez-Martini, L | 1 |
| Blanco, RA | 1 |
| Heffner, G | 1 |
| Ordóñez-Comparini, R | 1 |
| Javier, MA | 1 |
| Noche, ML | 1 |
| Sanchez, J | 1 |
| Rivero, A | 1 |
| Dal-Re, R | 2 |
| Azanza, JR | 1 |
| Riba, A | 1 |
| Morell, F | 1 |
7 reviews available for tulobuterol and Asthma
| Article | Year |
|---|---|
[Clinical application of transdermal beta-2 agonists for the wheezing diseases in childhood].
Topics: Adrenergic beta-2 Receptor Agonists; Asthma; Bronchitis; Bronchodilator Agents; Child; Child, Presch | 2013 |
Transdermal tulobuterol patch, a long-actingβ(2)-agonist.
Topics: Adrenergic beta-Agonists; Asthma; Bronchodilator Agents; Drug Approval; Evidence-Based Medicine; Hum | 2012 |
[The brittle asthmatic and the morning dipper].
Topics: Adrenergic beta-Agonists; Anti-Inflammatory Agents; Asthma; Bronchodilator Agents; Chromones; Circad | 1996 |
[Japanese guideline for the diagnosis and management of bronchial asthma (1998)--its results and reversion].
Topics: Administration, Cutaneous; Administration, Inhalation; Aminophylline; Androstadienes; Asthma; Eviden | 2001 |
[Long-acting beta 2-stimulants].
Topics: Administration, Cutaneous; Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adrenerg | 2001 |
[Development of transdermal formulation of tulobuterol for the treatment of bronchial asthma].
Topics: Administration, Cutaneous; Adrenergic beta-Agonists; Asthma; Chronotherapy; Clinical Trials as Topic | 2002 |
Tulobuterol in the management of obstructive airways disease in adults.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Aged; Asthma; Bronchodilator Agents; Femal | 1985 |
18 trials available for tulobuterol and Asthma
| Article | Year |
|---|---|
[Efficacy and safety of tulobuterol patch versus oral salbutamol sulfate in children with mild or moderate acute attack of bronchial asthma: a comparative study].
Topics: Acute Disease; Administration, Oral; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Female; | 2013 |
A 12-week, randomized, parallel-group, proof-of-concept study of tulobuterol patch and salmeterol inhaler as add-on therapy in adult-onset mild-to-moderate asthma.
Topics: Adult; Aged; Asthma; Bronchodilator Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hu | 2017 |
Effects of the addition of Beta2-agonist tulobuterol patches to inhaled corticosteroid in patients with asthma.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Aged; Asthma; | 2009 |
[Clinical effects of budesonide/formoterol combination drug in elder patients with asthma compared with budesonide plus tulobuterol patch combination treatment].
Topics: Aged; Aged, 80 and over; Asthma; Biomarkers; Breath Tests; Bronchodilator Agents; Budesonide; Drug T | 2012 |
Effects of transdermal tulobuterol in pediatric asthma patients on long-term leukotriene receptor antagonist therapy: results of a randomized, open-label, multicenter clinical trial in Japanese children aged 4-12 years.
Topics: Administration, Cutaneous; Adrenergic beta-Agonists; Asthma; Child; Child, Preschool; Female; Humans | 2013 |
[Clinical evaluation of tulobuterol patch in patients with mild or moderate persistent bronchial asthma-effects of long-term treatment on airway inflammation and hypersensitivity].
Topics: Administration, Cutaneous; Administration, Inhalation; Adrenergic beta-Agonists; Aged; Androstadiene | 2004 |
Clinical evaluation of a transdermal therapeutic system of the beta2-agonist tulobuterol in patients with mild or moderate persistent bronchial asthma.
Topics: Administration, Cutaneous; Adult; Anti-Asthmatic Agents; Asthma; Blood Proteins; Bronchial Hyperreac | 2004 |
The use of patch formulation of tulobuterol, a long-acting beta2-adrenoreceptor agonist, in the treatment of severe pediatric asthma.
Topics: Administration, Cutaneous; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Asthma; Be | 2006 |
Comparison of the clinical efficacy of salmeterol and sustained-release tulobuterol (patch) on inadequately controlled asthma patients on inhaled corticosteroids.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Adult; Aged; Albuterol; Anti-Inflammatory Agents | 2006 |
Comparison of the effects of tulobuterol patch and salmeterol in moderate to severe asthma.
Topics: Administration, Cutaneous; Aged; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Femal | 2006 |
[The efficacy and safety of tulobuterol tape in mild and moderate persistent asthma patients].
Topics: Adrenergic beta-2 Receptor Antagonists; Adult; Asthma; Bronchodilator Agents; Female; Humans; Male; | 2007 |
Addition of transdermal or inhaled long-acting Beta2-agonists in adult asthmatic patients treated with inhaled corticosteroids: switchover study from tulobuterol patch to salmeterol dry powder inhaler.
Topics: Administration, Cutaneous; Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albute | 2007 |
Can a new beta 2-agonist reduce the mortality of asthma?
Topics: Administration, Oral; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Airway Resistance; Albutero | 1990 |
Effects of a combined treatment theophylline and tulobuterol on nocturnal chronic asthma.
Topics: Adrenergic beta-Agonists; Adult; Aged; Asthma; Bronchodilator Agents; Double-Blind Method; Drug Admi | 1990 |
Prolonged treatment with oral and inhaled tulobuterol does not induce airways tachyphlaxis.
Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Airway Resistance; Asthm | 1990 |
Tulobuterol in childhood asthma: single dose ranging and repeated oral dose comparative studies.
Topics: Administration, Oral; Adolescent; Adrenergic beta-Agonists; Asthma; Child; Clinical Trials as Topic; | 1986 |
Open cross-over comparison of tulobuterol and fenoterol in asthmatic adult patients.
Topics: Adult; Albuterol; Asthma; Drug Evaluation; Fenoterol; Humans; Middle Aged; Random Allocation; Respir | 1988 |
Bronchodilator activity of a new inhaled beta 2-adrenoceptor agonist, tulobuterol and its protective effect in exercise-induced asthma.
Topics: Adult; Albuterol; Asthma; Asthma, Exercise-Induced; Blood Pressure; Bronchodilator Agents; Clinical | 1986 |
16 other studies available for tulobuterol and Asthma
| Article | Year |
|---|---|
Sustained release of tulobuterol from graphene oxide laden hydrogel to manage asthma.
Topics: Animals; Asthma; Delayed-Action Preparations; Graphite; Hydrogels; Rabbits; Rats; Rats, Sprague-Dawl | 2021 |
Cough variant and cough-predominant asthma are major causes of persistent cough: a multicenter study in Japan.
Topics: Adrenergic beta-Agonists; Adult; Asthma; Cough; Female; Humans; Japan; Male; Middle Aged; Prospectiv | 2013 |
Tulobuterol patch maintains diaphragm muscle contractility for over twenty-four hours in a mouse model of sepsis.
Topics: Administration, Cutaneous; Adrenergic beta-Agonists; Animals; Asthma; Diaphragm; Disease Models, Ani | 2009 |
Comparative study of skin permeation profiles between brand and generic tulobuterol patches.
Topics: Animals; Asthma; Bronchodilator Agents; Disease Models, Animal; Drugs, Generic; Female; Patents as T | 2010 |
[Questionnaire survey on the change of asthmatic response, adverse events and product usability due to drug switching between name-brand and generic tulobuterol tapes].
Topics: Aged; Asthma; Child, Preschool; Drug Substitution; Drug Utilization; Drugs, Generic; Female; Humans; | 2012 |
Effects of sustained-release tulobuterol on asthma control and beta-adrenoceptor function.
Topics: Adrenergic beta-Agonists; Adult; Analysis of Variance; Animals; Asthma; Delayed-Action Preparations; | 2002 |
Effects of a nitro compound patch on neuropathy in Churg-Strauss syndrome.
Topics: Adrenergic beta-Agonists; Asthma; Churg-Strauss Syndrome; Cyclophosphamide; Drug Hypersensitivity; F | 2003 |
Alteration of the circadian rhythm in peak expiratory flow of nocturnal asthma following nighttime transdermal beta2-adrenoceptor agonist tulobuterol chronotherapy.
Topics: Administration, Cutaneous; Adrenergic beta-Agonists; Adult; Anti-Asthmatic Agents; Asthma; Biologica | 2005 |
[Airway hypersensitivity and beta-adrenergic blockade in asthmatic patients, with special reference to insulin response to beta-stimulant].
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Airway Resistance; Asthma; Blood Glucose; Cyclic | 1983 |
Pharmacokinetics and pharmacodynamics of the tulobuterol patch, HN-078, in childhood asthma.
Topics: Administration, Cutaneous; Adult; Aged; Asthma; Blood Pressure; Child; Female; Humans; Male; Respira | 1995 |
[Effect of a patch formulation of tulobuterol on cough scores and PEF in patients with cough variant asthma].
Topics: Adrenergic beta-Agonists; Adult; Asthma; Bronchodilator Agents; Cough; Drug Evaluation; Female; Huma | 2000 |
Clinical characteristics of asthmatic patients prescribed various beta-agonist metered-dose inhalers at Yamagata University Hospital.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Ch | 2001 |
[Therapeutic aspects of intractable asthma].
Topics: Adult; Aged; Asthma; Cromolyn Sodium; Female; Humans; Ketotifen; Male; Middle Aged; ortho-Aminobenzo | 1988 |
[Pulmonary function tests in asthmatic children in treatment with tulobuterol].
Topics: Adolescent; Asthma; Bronchodilator Agents; Child; Female; Forced Expiratory Flow Rates; Forced Expir | 1989 |
Protective effect of tulobuterol on methacholine-induced bronchospasm in asthmatic children.
Topics: Adolescent; Asthma; Bronchial Spasm; Bronchodilator Agents; Child; Female; Forced Expiratory Volume; | 1988 |
Comparison of bronchodilator effect of tulobuterol and salbutamol aerosols in patients with asthma.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Forced Expiratory Volume; Hemodynamics; Humans; Mid | 1985 |